Engineered immune cells take on recurrent brain tumors
NCT ID NCT05627323
First seen Jan 30, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called CHM-1101 for people with a type of aggressive brain cancer (glioblastoma) that has returned or worsened. The treatment uses the patient's own immune cells, modified to better find and attack cancer cells that have a specific marker (MMP2). The main goals are to check safety, find the best dose, and see if it helps shrink tumors. About 42 adults with this condition will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME OF BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
St. David's South Austin Medical Center - Sarah Cannon - Austin
Austin, Texas, 78704, United States
Conditions
Explore the condition pages connected to this study.